PLYX

Polaryx Therapeutics, Inc. Common Stock

1.86

USD

-0.03

-1.59%

Oct 29, 15:59 UTC -4

Closed

Pre-Market

1.88

+0.02

+1.13%

Polaryx Therapeutics, Inc. Common Stock (PLYX) Earnings

PLYX Earnings Reports

Positive Surprise Ratio

PLYX beat 1 of 1 last estimates.

100%

Next Report

Date of Next Report

Estimate for Q-- -- (Revenue/ EPS)

Implied change from Q2 26 (Revenue/ EPS)

Implied change from Q-- -- (Revenue/ EPS)

Polaryx Therapeutics, Inc. Common Stock earnings per share and revenue

On Aug 13, 2026, PLYX reported earnings of -0.03 USD per share (EPS) for Q2 26, beating the estimate of -0.04 USD, resulting in a 26.47% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +4.00% price change (close before vs. close after earnings).

Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

NovoCure Limited Ordinary Shares

Report Date

Oct 29, 2026 For Q3 26

Estimate

-$0.24

Actual

-$0.09

Surprise

+63.88%

Phathom Pharmaceuticals, Inc. Common Stock

Report Date

Oct 29, 2026 For Q3 26

Estimate

-$0.14

Actual

$0.04

Surprise

+128.27%

Gilead Sciences Inc

Report Date

Oct 29, 2026 For Q3 26

Estimate

$2.24

Actual

$2.54

Surprise

+13.66%

Bristol-Myers Squibb Co.

Report Date

Oct 29, 2026 For Q3 26

Estimate

$1.20

Actual

$1.35

Surprise

+11.66%

Illumina Inc

Report Date

Oct 29, 2026 For Q3 26

Estimate

$1.38

Actual

$1.44

Surprise

+4.18%

Alnylam Pharmaceuticals, Inc.

Report Date

Oct 29, 2026 For Q3 26

Estimate

$1.65

Actual

$16.26

Surprise

+885.34%

Incyte Genomics Inc

Report Date

Oct 29, 2026 For Q3 26

Estimate

-$3.92

Actual

-$3.60

Surprise

+8.33%

Exelixis Inc

Report Date

Oct 29, 2026 For Q3 26

Estimate

$0.81

Actual

$0.94

Surprise

+15.64%

Kymera Therapeutics, Inc. Common Stock

Report Date

Oct 29, 2026 For Q3 26

Estimate

-$1.29

Actual

-$1.32

Surprise

-2.17%

Ligand Pharmaceuticals Inc.

Report Date

Oct 29, 2026 For Q3 26

Estimate

$2.42

Actual

$2.67

Surprise

+9.91%

FAQ

What were Polaryx Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?

For Q2 2026, Polaryx Therapeutics, Inc. Common Stock reported EPS of -$0.03, beating estimates by 26.47%, and revenue of $0.00, 0% as expectations.

How did the market react to Polaryx Therapeutics, Inc. Common Stock's Q2 2026 earnings?

The stock price moved up 4%, changed from $2.50 before the earnings release to $2.60 the day after.

When is Polaryx Therapeutics, Inc. Common Stock expected to report next?

The next earning report is scheduled for --.

What are the forecasts for Polaryx Therapeutics, Inc. Common Stock's next earnings report?

Based on -- analysts, Polaryx Therapeutics, Inc. Common Stock is expected to report EPS of -- and revenue of -- for Q-- --.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.